Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

Completed · Phase 4

Conditions studied: Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia

In brief

The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels. The main secondary objective is to evaluate whether the increase in glucose levels and rate of glucose abnormalities differs between Olanzapine and Risperidone during this treatment period. Additional secondary objectives of the study are to investigate similar questions with respect to glycohemoglobin, triglycerides and other measures of glucose and lipid metabolism. We hypothesize that Olanzapine will not be inferior to Risperidone in extent of increase in the primary outcome measure of serum glucose, and secondary measures of glycohemoglobin, insulin and lipids.

Key facts

Study ID

NCT00287820

Run by

Nathan Kline Institute for Psychiatric Research

People needed

46

Starts

2004-02-01

Expected to finish

2007-09-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis
• Schizophrenia or schizoaffective psychosis
• 18-65 years of age

You may not qualify if…

• Currently being treated with oral antidiabetics or insulin

Where it is running

• Manhattan Psychaitric Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.